Idiosyncratic adverse drug reactions: current concepts.

Area of Science:

• Pharmacology
• Immunology
• Toxicology

Background:

• Idiosyncratic drug reactions (IDRs) are a major cause of patient morbidity and mortality.
• They significantly complicate drug development due to unpredictable adverse events.
• Key target organs include skin, liver, and bone marrow.

Purpose of the Study:

• To explore the complex immunological mechanisms underlying idiosyncratic drug reactions.
• To review current models explaining drug-metabolite interactions with the immune system.
• To highlight the role of genetic factors, such as HLA, in IDR susceptibility.

Main Methods:

• Review of clinical characteristics and existing mechanistic models of IDRs.
• Discussion of hapten, P-I, and T-cell receptor interaction models.
• Inclusion of recent findings on abacavir and MHC interactions.
• Consideration of human leukocyte antigen (HLA) associations.

Main Results:

• Evidence suggests IDRs are largely immune-mediated, often involving chemically reactive drug species.
• Models like hapten, P-I, and reversible MHC-peptide interactions explain immune responses.
• Human leukocyte antigen (HLA) molecules are identified as significant risk factors for certain IDRs.
• Despite genetic predisposition, most individuals do not develop IDRs, indicating other factors are involved.

Conclusions:

• Understanding IDRs requires integrating knowledge of drug metabolism, immune responses, and genetic factors.
• Further research is needed to elucidate the precise mechanisms and the role of T-cell receptors and other individual differences.
• Immune tolerance is a critical factor in preventing IDRs, even in susceptible individuals.